Product
ATB200
4 clinical trials
1 indication
Indication
Pompe DiseaseClinical trial
A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-06-01